Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 6

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 6
---

                                            the amount of $10,000. The Company also issued to the Placement Agent (or its designees)
                                            warrants to purchase up to 15,325 shares of common stock (the “January 2025 Placement
                                            Agent Warrants”). The January 2025 Placement Agent Warrants have an exercise price
                                            equal to $6.382 per share and are exercisable upon issuance, or January 30, 2025, for twenty-four
                                            months from the date of issuance, or January 30, 2027.

The
                                            Company received net proceeds of approximately $804,346 from the offering, after deducting
                                            estimated offering expenses paid by the Company, including the Placement Agent fees. The
                                            Company intends to use the net proceeds from the offering for general corporate purposes,
                                            including working capital.

Supply
Chain Updates

In
February 2025, the FDA authorized the importation of Kodatef from Australia, to cover any future disruption of Arakoda in the U.S. market.
Kodatef is the branded version of tafenoquine for malaria prevention approved by the TGA for use in Australia. The Company made this
request of the FDA due to robust demand for Arakoda in late 2024/early 2025, and the potential for delays in the completion of new lots
of Arakoda currently being commercially validated by our key supplier, PCI. Although we anticipate that new commercial Arakoda lots will
enter the supply chain prior to the exhaustion of existing inventory, Kodatef will be available to cover any shortage through a specialty
pharmacy that already carries Arakoda, and has the capacity to ship to customers in all 50 states.

IRB
Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

On January 8, 2025, we announced that the approval
of an Investigational Review Board (IRB) sanctioned Phase II clinical study. The study (NCT06656351) will evaluate the efficacy and safety
of the ARAKODA® regimen (tafenoquine) over 90 days for treating patients with a presumptive diagnosis of chronic babesiosis who have
experienced severe fatigue with significant functional impairment for at least six months upon enrollment. Patient enrollment is expected
to begin in Q3 2025.

First
Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis

On
January